First human test for new IPF pill begins
NCT ID NCT07036029
Summary
This is an early safety study for a new extended-release tablet called NAL ER in people with Idiopathic Pulmonary Fibrosis (IPF). The main goal is to see if increasing doses are safe and well-tolerated, and to check for any effects on breathing. It will involve a small group of 10 participants who will be closely monitored in a clinic.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Medicines Evaluation Unit Ltd.
RECRUITINGManchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.